Protective Effects of Valproic Acid, a Histone Deacetylase Inhibitor, against Hyperoxic Lung Injury in a Neonatal Rat Model

PLoS One. 2015 May 4;10(5):e0126028. doi: 10.1371/journal.pone.0126028. eCollection 2015.

Abstract

Objective: Histone acetylation and deacetylation may play a role in the pathogenesis of inflammatory lung diseases. We evaluated the preventive effect of valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, on neonatal hyperoxic lung injury.

Methods: Forty newborn rat pups were randomized in normoxia, normoxia+VPA, hyperoxia and hyperoxia+VPA groups. Pups in the normoxia and normoxia+VPA groups were kept in room air and received daily saline and VPA (30 mg/kg) injections, respectively, while those in hyperoxia and hyperoxia+VPA groups were exposed to 95% O2 and received daily saline and VPA (30 mg/kg) injections for 10 days, respectively. Growth, histopathological, biochemical and molecular biological indicators of lung injury, apoptosis, inflammation, fibrosis and histone acetylation were evaluated.

Results: VPA treatment during hyperoxia significantly improved weight gain, histopathologic grade, radial alveolar count and lamellar body membrane protein expression, while it decreased number of TUNEL(+) cells and active Caspase-3 expression. Expressions of TGFβ3 and phospho-SMAD2 proteins and levels of tissue proinflammatory cytokines as well as lipid peroxidation biomarkers were reduced, while anti-oxidative enzyme activities were enhanced by VPA treatment. VPA administration also reduced HDAC activity while increasing acetylated H3 and H4 protein expressions.

Conclusions: The present study shows for the first time that VPA treatment ameliorates lung damage in a neonatal rat model of hyperoxic lung injury. The preventive effect of VPA involves HDAC inhibition.

MeSH terms

  • Animals
  • Biomarkers
  • Body Weight
  • Caspase 3 / metabolism
  • Disease Models, Animal
  • Histone Deacetylase Inhibitors / administration & dosage
  • Histone Deacetylase Inhibitors / pharmacology*
  • Hyperoxia / complications*
  • Hyperoxia / metabolism
  • Lung Injury / drug therapy
  • Lung Injury / etiology*
  • Lung Injury / metabolism
  • Lung Injury / mortality
  • Lung Injury / pathology*
  • Oxidation-Reduction
  • Oxidative Stress
  • Protective Agents / administration & dosage
  • Protective Agents / pharmacology*
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Rats
  • Valproic Acid / administration & dosage
  • Valproic Acid / pharmacology*

Substances

  • Biomarkers
  • Histone Deacetylase Inhibitors
  • Protective Agents
  • Proto-Oncogene Proteins c-bcl-2
  • Valproic Acid
  • Caspase 3

Grants and funding

The authors have no support or funding to report.